Daejeon, South Korea

Doo-Yong Lee

This inventor holds 1 USPTO granted patent. Top assignee: Hanvit MD Co., Ltd. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Doo-Yong Lee. Retrieved from https://idiyas.com/inventor/doo-yong-lee-sa04ldu4

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Doo-Yong Lee

Introduction

Doo-Yong Lee is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of medical devices, particularly in infusion technology. His work focuses on enhancing the accuracy and efficiency of infusion flow regulation.

Latest Patents

Doo-Yong Lee holds a patent for an infusion flow regulator, infusion flow regulating set, and infusion flow regulating method. The patent describes an innovative infusion flow regulator that sets a reference point within the manipulating range of a manipulation unit. This allows for the flow rate to be quickly and accurately tuned to a prescribed injection flow rate. The infusion flow regulating set includes the regulator, and the method utilizes this technology to improve infusion processes.

Career Highlights

Doo-Yong Lee is associated with Hanvit MD Co., Ltd., where he applies his expertise in developing advanced medical devices. His work has contributed to the company's reputation for innovation in the healthcare sector.

Conclusion

Doo-Yong Lee's contributions to infusion technology exemplify the impact of innovative thinking in medical device development. His patent reflects a commitment to improving patient care through enhanced medical solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…